Option Care Health, Inc. $OPCH Shares Acquired by Gamco Investors INC. ET AL

Gamco Investors INC. ET AL raised its holdings in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 36.8% in the 4th quarter, HoldingsChannel reports. The fund owned 369,002 shares of the company’s stock after buying an additional 99,244 shares during the quarter. Gamco Investors INC. ET AL’s holdings in Option Care Health were worth $11,756,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the company. Cornerstone Investment Partners LLC boosted its position in shares of Option Care Health by 3.4% in the 4th quarter. Cornerstone Investment Partners LLC now owns 9,773 shares of the company’s stock valued at $311,000 after purchasing an additional 318 shares during the period. Sheets Smith Wealth Management boosted its position in shares of Option Care Health by 1.3% in the 4th quarter. Sheets Smith Wealth Management now owns 26,167 shares of the company’s stock valued at $834,000 after purchasing an additional 326 shares during the period. Fifth Third Bancorp boosted its position in shares of Option Care Health by 21.9% in the 4th quarter. Fifth Third Bancorp now owns 2,328 shares of the company’s stock valued at $74,000 after purchasing an additional 419 shares during the period. Arizona State Retirement System boosted its position in shares of Option Care Health by 1.1% in the 3rd quarter. Arizona State Retirement System now owns 48,472 shares of the company’s stock valued at $1,346,000 after purchasing an additional 540 shares during the period. Finally, Blue Trust Inc. boosted its position in shares of Option Care Health by 8.0% in the 4th quarter. Blue Trust Inc. now owns 9,187 shares of the company’s stock valued at $293,000 after purchasing an additional 679 shares during the period. 98.05% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Option Care Health

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. bought 36,610 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was acquired at an average cost of $21.41 per share, with a total value of $783,820.10. Following the purchase, the director owned 450,000 shares in the company, valued at approximately $9,634,500. This represents a 8.86% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO John Charles Rademacher acquired 12,500 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was purchased at an average cost of $21.18 per share, with a total value of $264,750.00. Following the completion of the purchase, the chief executive officer directly owned 695,152 shares in the company, valued at $14,723,319.36. This represents a 1.83% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders acquired 73,264 shares of company stock valued at $1,548,316. Corporate insiders own 1.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on OPCH. Morgan Stanley set a $28.00 target price on Option Care Health in a research report on Wednesday, May 6th. Truist Financial set a $30.00 target price on Option Care Health in a research report on Friday, May 1st. Stephens set a $30.00 target price on Option Care Health in a research report on Friday, May 1st. Barrington Research decreased their target price on Option Care Health from $42.00 to $32.00 and set an “outperform” rating for the company in a research report on Friday, May 1st. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $26.00 target price on shares of Option Care Health in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Option Care Health currently has an average rating of “Moderate Buy” and a consensus target price of $31.25.

Option Care Health Stock Performance

Shares of OPCH stock opened at $19.69 on Tuesday. The company has a market cap of $3.09 billion, a price-to-earnings ratio of 15.26, a price-to-earnings-growth ratio of 1.09 and a beta of 0.68. The stock has a 50 day simple moving average of $26.62 and a 200-day simple moving average of $30.20. Option Care Health, Inc. has a 12-month low of $18.01 and a 12-month high of $36.80. The company has a current ratio of 1.64, a quick ratio of 1.07 and a debt-to-equity ratio of 0.85.

Option Care Health (NASDAQ:OPCH) last issued its earnings results on Thursday, April 30th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.03. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.39 billion. Option Care Health had a return on equity of 18.17% and a net margin of 3.64%.The company’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.40 EPS. Option Care Health has set its FY 2026 guidance at 1.820-1.920 EPS. On average, equities analysts forecast that Option Care Health, Inc. will post 1.64 EPS for the current year.

About Option Care Health

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.